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Introduction
Heparanase is an endo-b-glucuronidase that cleaves
highly potent heparan sulfate (HS) from its proteogly-
can, thereby triggering the inflammatory response in [1].
Thus, new anti-infective agents that interact with hepar-
anase may be promising tools for sepsis therapy. As a
novel anti-infective agent, peptide 19-2.5 (pep2.5)
belongs to the class of synthetic anti-lipopolysaccharide
peptides, however its activity is not restricted to Gram-
negative bacterial infection [2,3].
Objectives
To evaluate the interaction of pep2.5 with heparanase in
murine sepsis in vivo and in human sepsis ex vivo.
Methods
First, we used a model of murine cecal ligature and
puncture (CLP) sepsis to study the impact of pep2.5 on
heparanase in vivo in 12 NMRI mice. Mice were treated
with pep2.5 or NaCl 0.9%. Plasma was sampled 24h
after CLP. Second, we investigated whether pep2.5 inter-
acts with heparanase in human plasma samples ex vivo.
We added pep2.5 (20µg/ml) to plasma of 18 septic
shock patients according to the ACCP/SCCM defini-
tions and to plasma of 10 healthy volunteers. Hepara-
nase-levels, HS-levels and heparanase activity were
measured using ELISA (AMS Biotechnology, Oxon, Uni-
ted Kingdom). All data are given as mean ± standard
deviation. A t-test with Holm-Šídák correction was used
and a p-value < 0.05 was considered significant.
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Figure 1 (A) Heparanase level in CLP-mice. (B) Heparanase level in
human.*p < 0.05, **p < 0.005, ***p < 0.001.
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Results
Mice subjected to CLP without treatment displayed
higher heparanase levels in plasma compared to mice
treated with pep2.5 (p < 0.0001). Treatment with pep
2.5 resulted in lower heparanase activity (p < 0.0001)
and reduced HS-levels (p < 0.0001), compared to
untreated animals (Figure 1).
Septic shock patients (78% male) were 70 ± 15 years
old and healthy volunteers (50% male) were 67 ± 19
years old. Plasma heparanase levels, heparanase activity
and HS-levels were significantly higher in individuals
with septic shock than in healthy individuals (all p <
0.0001). The ex vivo addition of pep2.5 did not impact
heparanase levels, however heparanase activity and HS-
levels were decreased by adding pep2.5 to plasma of
septic shock patients (all p < 0.05, Figure 1).
Conclusions
The synthetic antimicrobial peptide 19-2.5 interacts with
heparanase in human and murine sepsis and reduces
levels of highly potent HS. Thus, peptide 19-2.5 may
have the potential for further development as a new
anti-infective drug in sepsis therapy.
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Figure 2 (C) Heparanase activity in CLP-mice. (D) Heparanase
activity in human. *p < 0.05, **p < 0.005, ***p < 0.001.
Figure 3 (E) Heparan sulfate level in CLP-mice. (F) Heparan sulfate
level in human. *p < 0.05, **p < 0.005, ***p < 0.001.
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